Back to search

Article

Naturally Selected CD7 CAR-T Therapy without Genetic editing Exerts Significant Antitumor Efficacy against Relapsed and Refractory Acute Myeloid Leukemia(R/R-AML)

2022-10-10

Abstract excerpt

<title>Abstract</title><p>Background Survival time for patients with relapsed and refractory acute myeloid leukemia (R/R-AML) remains threatened and treatment appears challenging. Chimeric antigen receptor T cell (CAR-T) has been widely used for hematologic malignancies. Current CAR-T therapies for acute myeloid leukemia mostly target myeloid-lineage antigens such as CD123 and CD33, which may have potential hemato...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
9d8908ba-5575-58a6-abc6-067d07ad87df
DOI
10.21203/rs.3.rs-2110527/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Naturally Selected CD7 CAR-T Therapy without Genetic editing Exerts Significant Antitumor Efficacy against Relapsed and Refractory Acute Myeloid Leukemia(R/R-AML)DOI 10.21203/rs.3.rs-2110527/v1
Select a neighboring publication to make it the new centre.